[Treatment of hyaline membrane disease with the plasminogen urokinase combination].
The authors present the results obtained using a therapeutic combinaison of plasminogen-urokinase in vivo in 14 premature infants suffering from respiratory distress. 86 % survived, a considerable improvement over classical survival rates. In addition it appeared that the duration of oxygen therapy was shorter, secondary to limitation of extension of the disease.
D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D010450:Endopeptidases / Q000627:therapeutic use*; D004789:Enzyme Activation; D006487:Hemostasis; D006801:Humans; D006819:Hyaline Membrane Disease / Q000188:drug therapy* / Q000401:mortality; D007231:Infant, Newborn; D010100:Oxygen / Q000627:therapeutic use; D010958:Plasminogen / Q000627:therapeutic use*; D011175:Positive-Pressure Respiration; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D010958:Plasminogen; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator; D010100:Oxygen
Traitement de la maladie des membranes hyalines par l'association plasminogène-urokinase